The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis

Human Pathology

Volumn 44, Issue 9, 2013, Pages 1804-1810

  Fassan, Matteo ^a   Pizzi, Marco ^a   Realdon, Stefano ^b   Balistreri, Mariangela ^a   Guzzardo, Vincenza ^a   Zagonel, Vittorina ^b   Castoro, Carlo ^b   Mastracci, Luca ^c   Farinati, Fabio ^a   Nitti, Donato ^a   Zaninotto, Giovanni ^a   Rugge, Massimo ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Gastroesophageal cancer; HER2; miRNAs

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MICRORNA; MIR125A5P; MIR125B; UNCLASSIFIED DRUG;

AGED; ARTICLE; BARRETT ESOPHAGUS; CARCINOGENESIS; CHROMOGENIC IN SITU HYBRIDIZATION; CONTROLLED STUDY; DOWN REGULATION; ESOPHAGEAL ADENOCARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; TUMOR BIOPSY; VALIDATION PROCESS;

BAC; BARRETT ADENOCARCINOMA; CHROMOGENIC IN SITU HYBRIDIZATION; CISH; GASTRIC CANCER; GASTROESOPHAGEAL CANCER; GC; HER2; HG; HIGH GRADE; HUMAN EPITHELIAL GROWTH FACTOR RECEPTOR 2; IEN; IHC; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTRAEPITHELIAL NEOPLASIA/DYSPLASIA; KRUSKAL-WALLIS TEST; KW; LG; LOW GRADE; MIRNAS; SH;

ADENOCARCINOMA; AGED; CELL DEDIFFERENTIATION; CELL LINE, TUMOR; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84883454157     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2013.01.023     Document Type: Article

References (24)

1. N.E. Hynes, and G. MacDonald ErbB receptors and signaling pathways in cancer Curr Opin Cell Biol 21 2009 177 184
2. M. Hofmann, O. Stoss, and D. Shi Assessment of a HER-2 scoring system for gastric cancer: results from a validating study Histopathology 52 2008 797 805
3. E. Rossi, V. Villanacci, and G. Bassotti TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma Histopathology 57 2010 81 89
4. M. Fassan, K. Ludwig, and M. Pizzi HER2 status in primary and metastatic esophagogastric junction adenocarcinomas Hum Pathol 43 2011 1206 1212
5. Y.S. Park, H.S. Hwang, and H.J. Park Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use? Hum Pathol 43 2012 413 422
6. M. Fassan, L. Mastracci, and F. Grillo Early HER2 dysregulation in gastric and oesophageal carcinogenesis Histopathology 61 2012 769 776
7. Y.J. Bang, E. Van Cutsem, and A. Feyereislova Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 2010 687 697
8. S.K. Shenouda, and S.K. Alahari MicroRNA function in cancer: oncogene or a tumour suppressor? Cancer Metastasis Rev 28 2009 369 378
9. G.K. Scott, A. Goga, and D. Bhaumik Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a-5p or miR-125b J Biol Chem 282 2007 1479 1486
10. N. Nishida, K. Mimori, and M. Fabbri MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab Clin Cancer Res 17 2011 2725 2733
11. G. Zaninotto, F. Minnei, and E. Guirroli The Veneto Region's Barrett's Oesophagus Registry: aims, methods, preliminary results Dig Liver Dis 39 2007 18 25
12. R.D. Odze, R.H. Riddell, and F.T. Bosman Premalignant lesions of the digestive system F.T. Bosman, F. Carneiro, Hruban Rh, N.D. Theise, WHO classification of tumours of the digestive system 2010 IARC Lyon, France 10 12
13. M. Rugge, G. Pennelli, and E. Pilozzi Gastritis: the histology report Dig Liver Dis 43 Suppl 4 2011 S373 S384
14. M. Rugge, A. Meggio, and G. Pennelli Gastritis staging in clinical practice: the OLGA staging system Gut 56 2007 631 636
15. M. Rugge, M. de Boni, and G. Pennelli Gastritis OLGA staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study Aliment Pharmacol Ther 31 2010 1104 1111
16. A. Fassina, R. Cappellesso, and V. Guzzardo Epithelial-mesenchymal transition in malignant mesothelioma Mod Pathol 25 2012 86 99
17. C. Mescoli, L. Albertoni, and S. Pucciarelli Isolated tumor cells in regional lymph nodes as relapse predictors in stage I and II colorectal cancer J Clin Oncol 30 2012 965 971
18. C. Mian, G. Pennelli, and M. Fassan MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome Thyroid 22 2012 890 896
19. M. Fassan, S. Volinia, and J. Palatini MicroRNA expression profiling in human Barrett's carcinogenesis Int J Cancer 129 2011 1661 1670
20. J.W. van Baal, R.E. Verbeek, and P. Bus MicroRNA-145 in Barrett's oesophagus: regulating BMP4 signalling via GATA6 Gut 2012 10.1136/gutjnl-2011- 301061 in press
21. A. Barker, K.M. Giles, and M.R. Epis Regulation of ErbB receptor signaling in cancer cells by microRNA Curr Opin Pharmacol 10 2010 655 661
22. M. Seike, A. Goto, and T. Okano MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers Proc Natl Acad Sci U S A 106 2009 12085 12090
23. G. Wang, W. Mao, and S. Zheng Epidermal growth factor receptor-regulated miR-125a-5p - a metastatic inhibitor of lung cancer FEBS J 276 2009 5571 5578
24. K.D. Cowden Dahl, and R. Dahl The epidermal growth factor receptor responsive miR-125a-5p represses mesenchymal morphology in ovarian cancer cells Neoplasia 11 2009 1208 1215